

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Janak PADIA et al

Title: UREA DERIVATIVES AS INHIBITORS FOR CCR-3
RECEPTOR

Appl. No.: Unassigned

Filing Date: 01/02/02

Examiner: Unassigned

Art Unit: Unassigned

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Commissioner for Patents
Box PCT
Washington, D.C. 20231

Sir:

Submitted herewith on Form PTO-1449 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56. A copy of each listed document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), within three (3) months of the date of entry of the national stage as set forth in 37 CFR §1.491.

RELEVANCE OF EACH DOCUMENT

Any document listed on the attached PTO-1449 was cited as being relevant during the prosecution of the corresponding International application. A copy of the International Search Report is attached setting forth the portion of each document considered relevant by the examiner. An English-language counterpart of the foreign-language documents has not been provided. The absence of a translation or an English-language counterpart document does not relieve the PTO from its duty to consider any submitted document (37 CFR §1.98 and MPEP§609). An English language abstract is attached for Document A5.

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO-1449 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

By 

Date January 2, 2002

FOLEY & LARDNER
Customer Number: 22428



22428

PATENT TRADEMARK OFFICE

Telephone: (202) 672-5407
Facsimile: (202) 672-5399

Stephen A. Bent
Attorney for Applicants
Registration No. 29,768

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 051023-0111	SERIAL NO. 10 / 019652 Unassigned
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		APPLICANT	Janak PADIA et al
		FILING DATE January 2, 2002	GROUP ART UNIT Unassigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
	A1	4,880,802	11/14/1989	Schohe et al.	514	222.2	

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
							YES	NO
	A2	0432442	06/19/1991	EPO				
	A3	0903349	03/24/1999	EPO				
	A4	888699	09/03/1953	Germany				X
	A5	9-278737	10/28/1997	Japan				abstract

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	A6	NAKAO, Kazuya et al. "Quantitative Structure – Activity Analyses of Novel Hydroxyphenylurea Derivatives as Antioxidants," <i>Bioorganic & Medicinal Chemistry</i> (1998), Vol. 6, pp. 849-868.
	A7	O'BRIEN, Patrick M. et al. "Inhibitors of Acyl-CoA:Cholestrerol O-Acyl Transferease (ACAT) as Hypocholesterolemic Agents. 8. ¹ Incorporation of Amide or Amine Functionalities into a Series of Disubstituted Ureas and Carbamates. Effects on ACAT Inhibition in Vitro and Efficacy in Vivo ² ," <i>J. med. Chem.</i> (1994), Vol. 37, No. 12, pp. 1810-1822, American Chemical Society.
	A8	ROST, William J. et al. "N-Aralkyl-N-methylaminoethyl Carbanilates as Hypocholesteremic Agents," <i>Journal of Pharmaceutical Sciences</i> (1967), Vol. 56, No. 12, pp. 1598-1603.

EXAMINER	DATE CONSIDERED

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.